MabThera/Rituxan

Sandoz says Humira biosimilar clears clinical hurdle

review of the company's biosimilar version Roche's immunotherapy drug Rituxan (rituximab), another blockbuster with sales of $4bn in the first half of the year.

Roche faces prospect of second Rituxan biosimilar in US

The US Food and Drug Administration (FDA) has started its review of a second biosimilar rival to Roche's blockbuster immunotherapy drug Rituxan, with Novartis' Sandoz unit seeking to dent its ... Rituxan is used to treat blood cancers including

Kite files first CAR-T candidate in Europe

cytokine-release syndrome (CRS), which can be fatal if not managed but has also been seen with antibody therapies such as Roche's MabThera (rituximab).

Ocrevus off to a flying start as Roche raises 2017 forecasts

Roche's mainstay biologic cancer therapies also held up well in the face of biosimilar competition in some markets, with Herceptin (trastuzumab) and MabThera/Rituxan (rituximab) both gaining 3% to

NICE backs Cancer Drugs Fund support for Roche's Gazyvaro

on Roche's MabThera (rituximab) - and as monotherapy for maintenance thereafter - via the CDF. ... Like MabThera, Gazyvaro targets the CD20 receptor but has been designed with sugar molecule side chains that improve its therapeutic and safety profile.

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]